Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05679908 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
A Phase 2 study, sponsored by Tonix Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT05679908 is a Phase 2 study that has completed, run by Tonix Pharmaceuticals. The registered enrollment target is 88 participants.
The verdict
NCT05679908, a Phase 2 study, has completed, sponsored by Tonix Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
This is a phase 2, double-blind, randomized, multicenter, placebo-controlled, three arm parallel study to evaluate the efficacy and safety of two different dosages (30 IU daily and 60 IU daily) of TNX-1900 in patients with chronic migraine.
Interventions
- DRUG Placebo Nasal Spray
- DRUG TNX-1900
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2023-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05679908
The ClinicalTrials.gov registry entry for NCT05679908 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tonix Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Nasal Spray is the first listed.
NCT05679908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05679908 about?
NCT05679908 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine". This is a phase 2, double-blind, randomized, multicenter, placebo-controlled, three arm parallel study to evaluate the efficacy and safety of two different dosages (30 IU daily and 60 IU daily) of TNX-1900 in patients with chronic migraine.
What is the current status of trial NCT05679908?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2022-12-06. Estimated completion is 2023-10-23.
What interventions are being tested in trial NCT05679908?
The interventions under investigation include: Placebo Nasal Spray (DRUG), TNX-1900 (DRUG).
Who is sponsoring clinical trial NCT05679908?
This trial is sponsored by Tonix Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.